The research team, led by Filippo Biondi and Rosalinda Madonna of the University of Pisa along with collaborators from institutions across Italy, systematically searched PubMed and Scopus databases following the PRISMA 2020 reporting guidelines. The protocol was prospectively registered in PROSPERO, the international registry for systematic review protocols, under registration number CRD420261368392. From the initial search, eight observational studies met the strict inclusion criteria, which required studies to report outcomes of either transcatheter or surgical mitral valve interventions in patients with active or prior cancer. Seven of these studies evaluated M-TEER specifically, and they accounted for the overwhelming majority of patients in the quantitative analysis: 1,522 patients with cancer and 4,716 controls without cancer.

The technical centerpiece of the analysis was the pooling of hazard ratios using random-effects models, the standard statistical approach when studies are expected to differ in their populations and methods. Where hazard ratios were not directly reported by the original studies, the researchers reconstructed them from published survival data using established methods for time-to-event synthesis, including techniques that extract individual-level survival estimates from published Kaplan-Meier curves. This methodological rigor matters because it allowed the team to combine evidence from heterogeneous observational cohorts into a single, statistically coherent estimate of the mortality risk attributable to cancer.

The headline result is unambiguous. In the pooled analysis of M-TEER studies, having cancer was associated with a 72 percent higher risk of all-cause mortality during follow-up, with a hazard ratio of 1.72 and a 95 percent confidence interval of 1.03 to 2.90. The confidence interval, while wide, excludes the null value of 1.0, indicating a statistically significant association. The degree of statistical heterogeneity between studies, measured by the I-squared statistic, was 74.8 percent, which is substantial and signals that the individual studies varied considerably in their populations and effect sizes. Importantly, the association remained consistent across prespecified subgroup and sensitivity analyses, suggesting the finding is not driven by any single outlier study.

What makes the result clinically fascinating is the contrast between short-term and long-term outcomes. The analysis found no significant differences between patients with and without cancer in 30-day mortality or in procedural success, meaning the catheter-based repair itself appears to work equally well in both groups. The clip-based edge-to-edge repair, which approximates the leaflets of the mitral valve using a device delivered through a vein in the leg, is far less invasive than open-heart surgery and has become the treatment of choice for patients deemed too frail or high-risk for conventional surgery. Cancer patients, who often fall precisely into this high-risk category, appear to derive the same immediate procedural benefit as anyone else.

So why do cancer patients die more often in the years that follow? The authors are careful to note that their evidence does not establish the factors responsible for this excess mortality. They outline several plausible mechanisms that future research must disentangle. Frailty, the age-related decline in physiological reserve, is more common in cancer patients and independently predicts death after cardiac procedures. Cardiovascular comorbidity, including pre-existing heart failure and coronary disease, may be more advanced in cancer patients by the time they reach the catheterization laboratory. Treatment-related comorbidity is another candidate: chemotherapy agents such as anthracyclines and targeted therapies like trastuzumab can injure the heart muscle, while chest radiation is a well-established cause of valvular heart disease, stiffening and calcifying the very valves that later require repair. The characteristics of the mitral regurgitation itself, whether it is degenerative or secondary to heart failure, may also differ between the groups, as may other residual confounders that observational data cannot fully adjust for.

One particularly intriguing detail from the analysis is that studies comparing matched cohorts found a non-significant difference in the hazard ratio for long-term mortality. Propensity matching, a statistical technique that pairs cancer patients with non-cancer patients of similar age, comorbidity burden, and valve anatomy, appears to attenuate the mortality signal. This suggests that at least part of the excess risk observed in unmatched analyses may reflect the fact that cancer patients undergoing M-TEER are systematically older, sicker, and more frail than their counterparts, rather than cancer itself being the direct cause of the mortality gap. It is a nuance that will shape how clinicians interpret the headline finding and how they counsel individual patients.

The study also highlights significant gaps in the evidence base. Data on heart failure worsening or hospitalization and on the need for reintervention were insufficient for quantitative synthesis, meaning the analysis could say nothing definitive about whether cancer patients experience more symptomatic recurrence or require more repeat procedures. Only one of the eight included studies assessed surgical mitral valve repair or replacement, so the findings speak almost exclusively to the transcatheter approach. The authors graded the risk of bias in the non-randomized studies using the ROBINS-I tool and the Newcastle-Ottawa Scale, and they are candid that the current evidence is limited by its observational nature and by residual confounding, the ever-present possibility that unmeasured differences between groups explain part of the observed effect.

The context in which this analysis arrives is one of rapidly converging epidemics. Cancer survival has improved dramatically across high-income countries over recent decades, and long-term cancer survivors now number in the tens of millions. Yet cardiovascular disease has emerged as a leading cause of death in this growing population, with several large cohort studies and meta-analyses showing that cardiovascular mortality can rival or even exceed cancer mortality among long-term survivors. Cancer therapies themselves, from anthracycline chemotherapy to mediastinal radiation, accelerate valvular degeneration, myocardial injury, and vascular disease. Valvular heart disease burden has been rising globally, and cardio-oncology, the discipline dedicated to managing the cardiovascular consequences of cancer and its treatment, has been formalized in the 2022 European Society of Cardiology guidelines developed with partner societies across Europe.

For the heart teams that decide between surgery, transcatheter repair, and medical therapy in cancer patients, the new analysis offers both reassurance and caution. The reassurance is that M-TEER can be delivered with equal procedural success and equal short-term safety in patients with cancer, removing one barrier to offering these patients a life-improving intervention. The caution is that the long-term prognosis of these patients remains worse, and the drivers of that excess mortality are unknown. The authors call for prospective cardio-oncology studies designed to improve patient selection and to identify which individuals with cancer are most likely to benefit from transcatheter mitral valve intervention. Until such studies arrive, the clip will keep being deployed, but the question of who truly benefits over the long haul remains open.

Subject of Research: Long-term outcomes of transcatheter mitral valve repair in patients with cancer

Article Title: Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis

Article References: Biondi, F., Cadeddu, C., Camilli, M., Cuomo, A., Mandoli, G. E., Minghini, A., Novo, G., & Madonna, R. (2026). Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis. GeroScience. https://doi.org/10.1007/s11357-026-02539-7

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02539-7

Keywords: cardio-oncology, transcatheter mitral valve repair, M-TEER, mitral regurgitation, cancer patients, meta-analysis, hazard ratio, heart failure, valvular heart disease, procedural success, long-term mortality, GeroScience

The central question the Iranian team asked was deceptively simple: can a quantitative calcium score measured on a gated CT scan predict whether a PTMC procedure will succeed on the table, in real time, before the patient leaves the catheterization laboratory? For decades, cardiologists have relied on the Wilkins score, an echocardiographic grading system that scores four features of the mitral valve, leaflet mobility, leaflet thickening, calcification, and the state of the subvalvular apparatus, each on a scale from one to four. A combined score above eight generally warns of a difficult procedure and poorer outcomes. The Wilkins score has endured because it is cheap and uses equipment every cardiology unit already owns, but it is subjective, semi-quantitative, and depends heavily on the experience of the reader. CT, by contrast, offers an objective, reproducible number derived directly from the density of calcium deposits in the valve tissue.

The study enrolled thirty patients with severe rheumatic mitral stenosis who were scheduled for PTMC. Each participant underwent both a standard transthoracic echocardiographic assessment, from which the Wilkins score was calculated, and an electrocardiogram-gated CT scan of the heart, from which the researchers derived a mitral valve calcium score, abbreviated MVCS. The investigators then defined procedural success in clinically meaningful terms: either a post-procedure mitral valve area of at least 1.5 square centimeters, or at least a fifty percent increase in valve area from the baseline measurement, without the development of significant mitral regurgitation, meaning moderate-severe or severe leakage through the valve. This dual criterion matters because a balloon that splits the valve too aggressively can convert a stenotic valve into a leaking one, an outcome that is often worse than the disease it was meant to treat.

The headline result was that procedural success was achieved in eighteen of the thirty patients, a rate of sixty percent. When the researchers compared the patients in whom the procedure failed with those in whom it succeeded, several patterns emerged. Failed procedures were associated with numerically higher Wilkins scores, averaging 9.55 compared with 8.58 in the success group, a difference that approached but did not clearly cross the threshold of conventional statistical significance, with a p value of 0.05. More strikingly, patients with failed procedures had dramatically higher CT-derived calcium scores on average, 16.08 versus 0.76, and a far greater burden of significant post-procedural mitral regurgitation, affecting 41.7 percent of the failure group compared with none of the success group.

Yet the researchers were careful, and admirably so, about what these numbers do and do not prove. Because the CT-derived calcium measurements followed a zero-inflated distribution, meaning that many patients had no detectable valve calcium at all while a few had very high scores, the team performed an exploratory binary analysis comparing patients with detectable calcium against those without. In that analysis, the association between calcium burden and procedural failure was numerically apparent but statistically inconclusive, with a p value of 0.929 for the comparison of mean calcium scores. In other words, the raw averages looked compelling, but with only thirty patients, the study lacked the statistical power to confirm that the CT calcium score independently predicts outcome. This is a crucial nuance that separates responsible science from headline-grabbing overclaiming, and it is a nuance the authors themselves emphasize in their conclusions.

What the study did establish more firmly was the continued relevance of the Wilkins score. Using receiver operating characteristic analysis, the investigators found that the Wilkins score showed moderate discrimination for the immediate procedural outcome, with an area under the curve of 0.72 and a ninety-five percent confidence interval spanning 0.51 to 0.93. An AUC of 0.72 means that if you picked one patient who succeeded and one who failed at random, the Wilkins score would correctly rank the higher-risk patient about seventy-two percent of the time. That is useful but far from definitive, which is precisely why the search for complementary imaging markers continues. The confidence interval, stretching from barely better than chance to quite good, reflects the small sample size and underscores the need for larger validation cohorts.

The biological logic behind the calcium hypothesis is sound and worth understanding. Rheumatic mitral stenosis is fundamentally a disease of fusion, the commissures, or junctions, between the valve leaflets are glued together by inflammation and scarring following rheumatic fever. The balloon works by forcibly splitting these fused commissures. When the leaflets are pliable and the fusion is the dominant problem, the balloon splits cleanly and the valve opens. But when the leaflets are heavily calcified, the calcium deposits act like concrete within the valve structure, resisting the balloon and, worse, fracturing unpredictably. A crack through a calcium plate rather than along a commissural line can tear the leaflet itself, producing the abrupt, severe regurgitation that the study observed in the failed procedures. Calcium, in this sense, is not merely a marker of chronicity but a direct mechanical obstacle to the procedure’s mechanism of action.

This is where CT scoring offers a genuine conceptual advance over echocardiography. The Wilkins calcification grade asks a sonographer to eyeball the valve and assign a subjective number. A CT calcium score, by contrast, applies an objective attenuation threshold, typically around 130 Hounsfield units, the same standard used for coronary artery calcium scoring, and quantifies the actual volume or mass of calcified tissue. The measurement is reproducible across readers and centers, can be acquired during a single breath-hold, and increasingly comes free of charge when patients already undergo cardiac CT for other reasons, such as pre-procedural planning for left atrial appendage occlusion or AFib ablation. For patients in whom a CT scan is already planned, extracting a mitral valve calcium score adds no radiation, no cost, and no additional visit.

The clinical implications, if the findings are confirmed, could be significant for the global burden of rheumatic heart disease. Although rheumatic fever has become rare in high-income countries, it remains endemic across South Asia, sub-Saharan Africa, the Middle East, and parts of Latin America, where PTMC is often the only realistic treatment option given the scarcity of cardiac surgery capacity. A reliable pre-procedural predictor of failure would allow clinicians to triage patients more intelligently, reserving balloon commissurotomy for valves likely to respond and directing high-calcium valves toward surgical repair or replacement where feasible. It could also inform procedural technique itself, since operators might approach heavily calcified valves with smaller balloon sizes or staged dilations to reduce the risk of catastrophic leaflet tearing.

The authors of the study are appropriately measured in their conclusions, stating that CT calcium scoring may serve as a complementary anatomical marker in selected patients but that larger studies are needed to define its incremental value over the Wilkins score. That framing is exactly right for a thirty-patient exploratory investigation. What the study provides is a proof of concept and a methodological template: a rigorous definition of success, a quantitative imaging biomarker, and an honest statistical treatment of a skewed data distribution. If subsequent multicenter trials with hundreds of patients confirm that a threshold CT calcium score reliably identifies valves destined to fail balloon dilation, the mitral valve calcium score could join the Wilkins score as a standard element of the pre-PTMC workup, giving cardiologists in resource-limited settings a sharper tool for deciding which valves can be saved by a balloon and which require something more. For now, the message for patients and clinicians alike is one of cautious optimism: the technology to see inside a stiffened valve in exquisite detail already exists, and the evidence that it can predict procedural fate is accumulating, one carefully designed study at a time.

Subject of Research: CT-based mitral valve calcium scoring as a predictor of immediate outcomes after percutaneous transvenous mitral commissurotomy in rheumatic mitral stenosis

Article Title: CT mitral valve calcium score and immediate outcomes after percutaneous transvenous mitral commissurotomy

Article References: Eini, P., Jolfayi, A. G., Firouzi, A., Rafiee, F., Ranjbar, B., Kaviani, R., Parsaee, M., Alemzadeh-Ansari, M. J., Bakhshandeh, H., Maleki, M., & Houshmand, G. (2026). CT mitral valve calcium score and immediate outcomes after percutaneous transvenous mitral commissurotomy. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02843-w

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02843-w

Keywords: rheumatic mitral stenosis, PTMC, mitral valve calcium score, computed tomography, Wilkins score, echocardiography, mitral regurgitation, balloon commissurotomy, cardiac imaging, procedural outcomes, valvular heart disease, BMC Medical Imaging